2024 Q1 Form 10-K Financial Statement
#000149315224008361 Filed on February 29, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 Q2 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $2.490M | $1.707M | $3.337M |
YoY Change | 78.0% | ||
% of Gross Profit | |||
Research & Development | $960.0K | $773.0K | $1.021M |
YoY Change | 100.84% | 124.06% | |
% of Gross Profit | |||
Depreciation & Amortization | $35.00K | $31.00K | $3.000K |
YoY Change | 3400.0% | ||
% of Gross Profit | |||
Operating Expenses | $3.450M | $2.480M | $4.358M |
YoY Change | 52.32% | 90.18% | |
Operating Profit | -$3.450M | -$2.093M | |
YoY Change | 52.32% | ||
Interest Expense | $4.000K | -$1.000K | -$146.0K |
YoY Change | -97.04% | -99.55% | |
% of Operating Profit | |||
Other Income/Expense, Net | -$7.236M | -$72.00K | |
YoY Change | |||
Pretax Income | -$8.460M | -$9.717M | -$4.576M |
YoY Change | 537.6% | ||
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$8.460M | -$9.717M | -$7.149M |
YoY Change | 250.31% | 537.6% | |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$0.27 | -$0.08 | |
Diluted Earnings Per Share | -$0.27 | -$0.63 | -$0.22 |
COMMON SHARES | |||
Basic Shares Outstanding | 32.63M shares | 28.23M shares | |
Diluted Shares Outstanding | 31.13M shares | 28.23M shares |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2023 Q2 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $8.158M | $9.163M | $11.38M |
YoY Change | |||
Cash & Equivalents | $8.158M | $9.163M | $11.38M |
Short-Term Investments | |||
Other Short-Term Assets | $18.00K | $16.00K | $382.0K |
YoY Change | -46.67% | ||
Inventory | |||
Prepaid Expenses | $746.0K | $36.00K | |
Receivables | $300.0K | ||
Other Receivables | |||
Total Short-Term Assets | $8.922M | $9.215M | $11.76M |
YoY Change | 251.05% | ||
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $770.0K | $797.0K | $2.084M |
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $2.477M | $2.606M | $2.084M |
YoY Change | 18.51% | ||
TOTAL ASSETS | |||
Total Short-Term Assets | $8.922M | $9.215M | $11.76M |
Total Long-Term Assets | $2.477M | $2.606M | $2.084M |
Total Assets | $11.40M | $11.82M | $13.84M |
YoY Change | 145.05% | ||
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $814.0K | $1.444M | $598.0K |
YoY Change | |||
Accrued Expenses | $372.0K | $362.0K | $344.0K |
YoY Change | |||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $459.0K | $141.0K | $0.00 |
YoY Change | 135.0% | ||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $13.99M | $9.183M | $942.0K |
YoY Change | 29.83% | ||
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $1.277M | $1.385M | $1.549M |
YoY Change | |||
Total Long-Term Liabilities | $1.277M | $1.385M | $1.549M |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $13.99M | $9.183M | $942.0K |
Total Long-Term Liabilities | $1.277M | $1.385M | $1.549M |
Total Liabilities | $15.26M | $10.57M | $2.491M |
YoY Change | 19.82% | ||
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$32.82M | -$24.36M | |
YoY Change | 209.41% | ||
Common Stock | |||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$3.863M | $1.253M | $11.35M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $11.40M | $11.82M | $13.84M |
YoY Change | 145.05% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 Q2 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$8.460M | -$9.717M | -$7.149M |
YoY Change | 250.31% | 537.6% | |
Depreciation, Depletion And Amortization | $35.00K | $31.00K | $3.000K |
YoY Change | 3400.0% | ||
Cash From Operating Activities | -$4.275M | -$1.601M | -$3.661M |
YoY Change | 109.97% | 36.49% | 139.91% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $8.000K | $2.000K | $80.00K |
YoY Change | -85.71% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | -$8.000K | -$2.000K | -$80.00K |
YoY Change | -85.71% | ||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $3.278M | 0.000 | 12.85M |
YoY Change | -77.5% | -100.0% | 215.41% |
NET CHANGE | |||
Cash From Operating Activities | -$4.275M | -1.601M | -3.661M |
Cash From Investing Activities | -$8.000K | -2.000K | -80.00K |
Cash From Financing Activities | $3.278M | 0.000 | 12.85M |
Net Change In Cash | -$1.005M | -1.603M | 9.112M |
YoY Change | -108.06% | -264.07% | 257.47% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$4.275M | -$1.601M | -$3.661M |
Capital Expenditures | $8.000K | $2.000K | $80.00K |
Free Cash Flow | -$4.283M | -$1.603M | -$3.741M |
YoY Change | 104.73% | 145.15% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001958777 | |
CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
usd | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
usd | |
CY2022Q4 | FBLG |
Parent Company Payable
ParentCompanyPayable
|
usd | |
CY2022Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
usd | |
CY2023Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
usd | |
CY2023Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
usd | |
CY2023Q4 | FBLG |
Net Parent Investment
NetParentInvestment
|
usd | |
CY2022 | FBLG |
Fair Value Adjustment Of Liability Instrument
FairValueAdjustmentOfLiabilityInstrument
|
usd | |
CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
usd | |
CY2022 | FBLG |
Deemed Dividend
DeemedDividend
|
usd | |
CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
usd | |
CY2022 | us-gaap |
Derivative Loss On Derivative
DerivativeLossOnDerivative
|
usd | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
usd | |
CY2022 | FBLG |
Increase Decrease In Change In Payable To Parent
IncreaseDecreaseInChangeInPayableToParent
|
usd | |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
usd | |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
CY2023 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
usd | |
CY2022 | FBLG |
Rofn Agreement Payments To Parent
RofnAgreementPaymentsToParent
|
usd | |
CY2023 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
usd | |
CY2022 | FBLG |
Proceeds From Issuance Of Preferred Stock And Preference Stock1
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1
|
usd | |
CY2023 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
CY2022 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
usd | |
CY2023 | FBLG |
Addition To Derivative Liability For Debt Issuance Discount
AdditionToDerivativeLiabilityForDebtIssuanceDiscount
|
usd | |
CY2023 | FBLG |
Obtaining Operating Lease Rightofuse Asset And Liability
ObtainingOperatingLeaseRightofuseAssetAndLiability
|
usd | |
CY2022 | FBLG |
Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest
IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest
|
usd | |
CY2022 | FBLG |
Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock
ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock
|
usd | |
CY2022 | FBLG |
Additions To Accounts Payable And Accrued Expenses For Purchases Of Property And Equipment
AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment
|
usd | |
CY2022 | FBLG |
Deemed Dividend
DeemedDividend
|
usd | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
usd | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
usd | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
usd | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
usd | |
CY2022Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
usd | |
CY2021Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
usd | |
CY2023Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
usd | |
CY2022Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
usd | |
CY2023Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
usd | |
CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
usd | |
CY2023Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
usd | |
CY2023 | FBLG |
Effective Income Tax Rate Reconciliation Prior Year Net Operating Loss Deferred Tax Assets
EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets
|
pure | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
pure | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
usd | |
CY2023Q4 | FBLG |
Deferred Tax Liabilities Unamortized Debt Discount
DeferredTaxLiabilitiesUnamortizedDebtDiscount
|
usd | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
usd | |
CY2023Q4 | FBLG |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
usd | |
CY2023 | dei |
Document Type
DocumentType
|
10-K | |
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-41934 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
FibroBiologics, Inc. | |
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
86-3329066 | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
455 E. Medical Center Blvd | |
CY2023 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 300 | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Houston | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
TX | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
77598 | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
77598 | |
CY2023 | dei |
City Area Code
CityAreaCode
|
(281) | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
651-5150 | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2023 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
0 | usd |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
32634366 | shares |
CY2023 | dei |
Auditor Name
AuditorName
|
WithumSmith+Brown, PC. | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
East Brunswick, New Jersey | |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
100 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9163000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2266000 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
36000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
29000 | usd |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
300000 | usd |
CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
16000 | usd |
CY2022Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
30000 | usd |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
9215000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
2625000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
797000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1809000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2199000 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
11821000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
4824000 | usd |
CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1444000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
758000 | usd |
CY2023Q4 | FBLG |
Parent Company Payable
ParentCompanyPayable
|
141000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
362000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
326000 | usd |
CY2023Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
7236000 | usd |
CY2022Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
538000 | usd |
CY2022Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
5451000 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9183000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7073000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1385000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1747000 | usd |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
10568000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
8820000 | usd |
CY2022Q4 | FBLG |
Net Parent Investment
NetParentInvestment
|
1461000 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
25609000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
2414000 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-24357000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-7872000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1253000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3996000 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11821000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
4824000 | usd |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2368000 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1147000 | usd |
CY2023 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6521000 | usd |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3320000 | usd |
CY2023 | us-gaap |
Operating Expenses
OperatingExpenses
|
8889000 | usd |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
4467000 | usd |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8889000 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4467000 | usd |
CY2023 | FBLG |
Fair Value Adjustment Of Liability Instrument
FairValueAdjustmentOfLiabilityInstrument
|
7236000 | usd |
CY2023 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-213000 | usd |
CY2023 | us-gaap |
Interest Expense
InterestExpense
|
147000 | usd |
CY2022 | us-gaap |
Interest Expense
InterestExpense
|
654000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16485000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5121000 | usd |
CY2023 | FBLG |
Deemed Dividend
DeemedDividend
|
-2573000 | usd |
CY2023 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19058000 | usd |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5121000 | usd |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.68 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.68 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.18 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.18 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
28230842 | shares |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28230842 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
28230842 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28230842 | shares |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1290000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1290000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
2150000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
265000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5121000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3996000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3996000 | usd |
CY2023 | FBLG |
Sale Of Series B Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
14945000 | usd |
CY2023 | FBLG |
Sale Of Series B One Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
1193000 | usd |
CY2023 | FBLG |
Issuance Of Series B Adjustments To Additional Paid In Capital Conversion Of Notes And Accrued Interest
IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
|
6404000 | usd |
CY2023 | FBLG |
Deemed Dividend Related To Rofn Agreement Derivative Liability
DeemedDividendRelatedToRofnAgreementDerivativeLiability
|
-2573000 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
1765000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16485000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1253000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1253000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16485000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5121000 | usd |
CY2023 | FBLG |
Fair Value Adjustment Of Liability Instrument
FairValueAdjustmentOfLiabilityInstrument
|
7236000 | usd |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1765000 | usd |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
265000 | usd |
CY2023 | us-gaap |
Derivative Loss On Derivative
DerivativeLossOnDerivative
|
72000 | usd |
CY2023 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
81000 | usd |
CY2022 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
389000 | usd |
CY2023 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
390000 | usd |
CY2022 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
94000 | usd |
CY2023 | us-gaap |
Depreciation
Depreciation
|
47000 | usd |
CY2023 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
7000 | usd |
CY2022 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-8000 | usd |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
671000 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
525000 | usd |
CY2023 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-14000 | usd |
CY2022 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
6000 | usd |
CY2023 | FBLG |
Increase Decrease In Change In Payable To Parent
IncreaseDecreaseInChangeInPayableToParent
|
141000 | usd |
CY2023 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-326000 | usd |
CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-220000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6401000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4066000 | usd |
CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
495000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-495000 | usd |
CY2022 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
225000 | usd |
CY2023 | FBLG |
Rofn Agreement Payments To Parent
RofnAgreementPaymentsToParent
|
2645000 | usd |
CY2023 | us-gaap |
Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
|
300000 | usd |
CY2022 | us-gaap |
Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
|
-300000 | usd |
CY2022 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
4300000 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
14945000 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
2150000 | usd |
CY2023 | FBLG |
Proceeds From Issuance Of Preferred Stock And Preference Stock1
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1
|
1193000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
13793000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5925000 | usd |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
6897000 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
1859000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2266000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
407000 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9163000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2266000 | usd |
CY2023 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2000 | usd |
CY2022 | FBLG |
Addition To Derivative Liability For Debt Issuance Discount
AdditionToDerivativeLiabilityForDebtIssuanceDiscount
|
538000 | usd |
CY2022 | FBLG |
Obtaining Operating Lease Rightofuse Asset And Liability
ObtainingOperatingLeaseRightofuseAssetAndLiability
|
2293000 | usd |
CY2023 | FBLG |
Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest
IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest
|
5866000 | usd |
CY2023 | FBLG |
Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock
ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock
|
538000 | usd |
CY2023 | FBLG |
Additions To Accounts Payable And Accrued Expenses For Purchases Of Property And Equipment
AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment
|
349000 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-24357000 | usd |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9163000 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
1924000 | usd |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_847_eus-gaap--UseOfEstimates_zwt2zNhO5J4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zw1DrwJNNSH8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zbzlq04VIvr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIVIo5Wbo1Te">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1s2CkMyVJma" title="Federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> | |
CY2023Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | usd |
CY2023Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
0 | usd |
CY2022Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
0 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16485000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5121000 | usd |
CY2023 | FBLG |
Deemed Dividend
DeemedDividend
|
-2573000 | usd |
CY2023 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19058000 | usd |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5121000 | usd |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
28230842 | shares |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28230842 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
28230842 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28230842 | shares |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.68 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.68 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.18 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.18 | |
CY2022Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
5600000 | usd |
CY2022Q4 | FBLG |
Capital Stock In Excess
CapitalStockInExcess
|
10000000 | usd |
CY2022 | us-gaap |
Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
|
801145 | shares |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
844000 | usd |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
47000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
797000 | usd |
CY2023 | us-gaap |
Depreciation
Depreciation
|
47000 | usd |
CY2023Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
7236000 | usd |
CY2023Q4 | FBLG |
Liability Instrument
LiabilityInstrument
|
7236000 | usd |
CY2023Q4 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
7236000 | usd |
CY2022Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
538000 | usd |
CY2022Q4 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
538000 | usd |
CY2023Q4 | us-gaap |
Share Price
SharePrice
|
15.00 | |
CY2022Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
4300000 | usd |
CY2022 | us-gaap |
Conversion Of Stock Description
ConversionOfStockDescription
|
a) a 15% discount to the offering price of the Company’s common stock in the event of an initial public offering of the Company or b) the quotient of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the 2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion option was recorded at the time the notes were issued and as of December 31, 2022. | |
CY2023 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
65000 | usd |
CY2022 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
265000 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
5600000 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
149000 | usd |
CY2022Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
5451000 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
12500000 | shares |
CY2022 | us-gaap |
Stock Issued During Period Shares Employee Benefit Plan
StockIssuedDuringPeriodSharesEmployeeBenefitPlan
|
51250 | shares |
CY2022 | us-gaap |
Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
|
168000 | usd |
CY2023Q1 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
35000000 | usd |
CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
10000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
100000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
CY2023Q4 | us-gaap |
Debt Instrument Convertible Type Of Equity Security
DebtInstrumentConvertibleTypeOfEquitySecurity
|
The Series C Preferred Stock is not entitled to dividends, has a liquidation preference of $18.00 per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock. | |
CY2023Q4 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-4 reverse stock split | |
CY2023 | FBLG |
Description Of Share Subscription Agreement
DescriptionOfShareSubscriptionAgreement
|
The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather than completing a public listing of its shares. | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | pure |
CY2023 | FBLG |
Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
|
0.092 | pure |
CY2022 | FBLG |
Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
|
0.008 | pure |
CY2022 | FBLG |
Effective Income Tax Rate Reconciliation Prior Year Net Operating Loss Deferred Tax Assets
EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets
|
0.061 | pure |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.016 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.000 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.019 | pure |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.102 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.244 | pure |
CY2023 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | pure |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
2005000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
896000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
675000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
299000 | usd |
CY2023Q4 | FBLG |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Lease Liability
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability
|
367000 | usd |
CY2022Q4 | FBLG |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Lease Liability
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability
|
435000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
156000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
81000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
123000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
17000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
|
31000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
3326000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
1759000 | usd |
CY2023Q4 | FBLG |
Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
|
380000 | usd |
CY2022Q4 | FBLG |
Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
|
462000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
11000 | usd |
CY2022Q4 | FBLG |
Deferred Tax Liabilities Unamortized Debt Discount
DeferredTaxLiabilitiesUnamortizedDebtDiscount
|
31000 | usd |
CY2023Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
391000 | usd |
CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
493000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
2935000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
1266000 | usd |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2023Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
9547000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
680000 | usd |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | usd |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | usd |
CY2021Q4 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P126M | |
CY2023Q4 | FBLG |
License Fee
LicenseFee
|
15000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P62M | |
CY2023Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P12M | |
CY2023Q2 | us-gaap |
Payments For Rent
PaymentsForRent
|
6000 | usd |
CY2023Q3 | us-gaap |
Payments For Rent
PaymentsForRent
|
7000 | usd |
CY2023 | us-gaap |
Payments For Rent
PaymentsForRent
|
685000 | usd |
CY2022 | us-gaap |
Payments For Rent
PaymentsForRent
|
392000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
477000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
487000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
544000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
509000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
2017000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
270000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1747000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
362000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1385000 | usd |
CY2022Q3 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
300000 | usd |
CY2022Q4 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
60000 | usd |
CY2023Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
300000 | usd |
CY2023Q1 | FBLG |
Payments For Equity Investments
PaymentsForEquityInvestments
|
323000 | usd |
CY2023 | us-gaap |
Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
|
16418000 | usd |
CY2023 | FBLG |
Payments For Equity Investments
PaymentsForEquityInvestments
|
2322000 | usd |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
101250 | shares |
CY2022Q3 | us-gaap |
Share Price
SharePrice
|
3.28 | |
CY2023Q3 | us-gaap |
Share Price
SharePrice
|
3.28 | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
3689750 | shares |
CY2023Q1 | us-gaap |
Share Price
SharePrice
|
2.28 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2500 | shares |
CY2023Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
8711500 | shares |
CY2022Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
12398750 | shares |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1765000 | usd |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
265000 | usd |
CY2022 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
168000 | usd |
CY2023Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
5039000 | usd |
CY2023 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.039 | pure |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.041 | pure |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.90 | pure |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1 | pure |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P7Y | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.80 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.64 |